Last reviewed · How we verify
NCT04215926: NAFLDIH
NAFLD in HIV-infected Patients
trial testing No intervention; cross-sectional study in HIV-infection/Aids in 400 participants. Status unknown.
30 October 2020
Quick facts
| Lead sponsor | Shanghai Public Health Clinical Center |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 5 December 2019 |
| Primary completion | 30 October 2020 |
| Estimated completion | 30 November 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- No intervention; cross-sectional study
Conditions studied
- HIV-infection/Aids — all drugs for HIV-infection/Aids →
- NAFLD — all drugs for NAFLD →
Sponsor
Shanghai Public Health Clinical Center
Who can join
Adults 18 to 70, any sex, with HIV-infection/Aids or NAFLD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The prevalence of NAFLD (nonalcoholic fatty liver disease) in HIV-infected patients is higher than that in general population, but the causes of morbidity and pathogenesis have not been fully explored. The investigators are planning to consecutively enroll 400 cases HIV-positive outpatients, and to detect NAFLD by ultrasound. The fecal and blood samples were also collected to explore the mechanism of NAFLD. The investigators aimed to determine the prevalence and risk factors of NAFLD in HIV infected patients.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Evaluation of ten diagnostic models for metabolic dysfunction-associated fatty liver disease in lean people living with HIV.
Xu W, Liu D, Zhang R, Chen J, et al · · 2025 · PMID 41013384 · DOI 10.1186/s12879-025-11540-y -
Prevalence and Risk Factors of Liver Fibrosis Among People With HIV and Metabolic Dysfunction-Associated Steatotic Liver Disease.
Xu W, Liu D, Zhang R, Chen J, et al · · 2025 · PMID 40667432 · DOI 10.1093/ofid/ofaf369
Verify or expand the search:
- PubMed search for NCT04215926
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Shanghai Public Health Clinical Center trials
Trials by the same sponsor.
- NCT07526363 — Real-world Cohort Study of Antiretroviral Therapy in HIV Patients With Opportunistic Infections · not yet recruiting
- NCT06940375 — Incidence of Liver Disease-Related Outcomes in People With HIV · recruiting
- NCT06926569 — Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis · NA · not yet recruiting
- NCT06768697 — Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant · EARLY_PHASE1 · not yet recruiting
- NCT05129189 — Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04215926 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Public Health Clinical Center
- Last refreshed: 4 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04215926.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing